Association of *HLA-DR* Alleles With Pulmonary Cystic Fibrosis

alireza asef

Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Hossein Ali Ghaffaripour

Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

hamidreza Jamaati

Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

Mohammad Varahram

Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Ian Adcock

Cell and Molecular Biology Group, Airways Disease Section, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London, UK

Esmail Mortaz (✉ emortaz@gmail.com)

Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Article

Keywords: HLA-DRB1, SSP-PCR, lung cystic fibrosis

Posted Date: January 6th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-138843/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Cystic fibrosis (CF) is the most common lethal autosomal recessive disease in white Caucasians. It affects many organs including the lung, pancreas, and liver. Whilst CF is a monogenic disease, several studies revealed a complex relationship between genotype and clinical phenotype of diseases.

Objective of study: We examined the expression of HLA class II alleles among Iranian CF patients in relation to disease-related bacterial infection.

Materials and methods: This study was conducted on 50 CF patients (27 males, 23 females aged 15.5 ± 6.5 years) hospitalized in the Masih Daneshvari hospital in Tehran, Iran and 50 healthy age- and gender-matched control subjects. 5ml whole blood was harvested and after isolation of genomic DNA, HLA-DRB1 subtypes were determined by Single Specific Primer Polymerase Chain Reaction (SSP-PCR) methods.

Results: HLA-DRB1*10 was less frequent than HLA-DRB1*04 and HLA-DRB1*11 but none reached significance. 16 CF patients with high serum IgE levels (430.25 ± 219.7 IU/ml) and 27 CF patients positive for *Pseudomonas aeruginosa* colonization were most closely associated with the HLA-DRB1*04 allele. 31 CF patients had candida *Albicans* colonization which was most closely associated with HLA-DRB1*11. 3 CF patients had allergic bronchopulmonary aspergillosis (ABPA) and two were diabetic.

Discussion: The DR4 and DR11 serotypes that recognize the HLA-DRB1*04 and HLA-DRB1*11 gene products respectively, are not significantly enriched in the Iranian CF population. Further research should be conducted on DR4 and DR11 in CF patients to understand their possible role in infection and IgE expression.

Trial registration: The study was approved by Ethical committee of Masih Daneshvari Hospital IR.SBMU.NRITLD.1395.234

Introduction

Cystic fibrosis (CF) is an autosomal impairment caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene located on chromosome 7q31.27 [1]. This gene encodes a trans-membrane chloride ion channel and mutations in this gene results in disturbed NaCl flux and fluid transportation into and out of the cells in various organs of the body including the lung, pancreas, gastrointestinal tract and reproductive organs. As a result the secretions from these tissues are thick and sticky and sweat gland secretions contain high levels of salt [1, 2]. The prevalence of CF is 1 in 2-3000 births and approximately 2000 gene mutations have been reported with the F508del mutation being the most common defect which is seen in 70% of CF cases [3, 4]. This disorder has been observed in all races but is mainly reported in northern Europeans [5]. Atopy, as defined by a positive skin test, increased total serum IgE and allergic symptoms is often observed in CF patients [6, 7].

The thick and sticky secretions in the respiratory tract of CF patients provide ideal conditions for chronic infections which cause more than 90% of all CF deaths [8]. The most common bacterial species found in CF patients are *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Burkholderia Cepacia* [9]. *Pseudomonas aeruginosa* is the major bacterial agent causing CF lung infections and has been associated with disease progression. In addition, *Candida albicans* is a common opportunist fungal infection that colonizes the respiratory tract of CF patients [10]. A previous study found a strong association between IgE and *Candida albicans* and Allergic Bronchopulmonary Aspergillosis (ABPA) which suggests that IgE may be an immunologic marker for the progression of ABPA in CF patients [11].

Human Leukocyte Antigen (HLA) complex, which is located on chromosome 6, p21, plays an important role in regulating the immune system [12]. HLA is associated with a large number of diseases [13-19] including allergic diseases such as psoriasis and asthma where a link with HLA-DR4 and HLA-DR7 has been described [20, 21]. The presence of HLA-DR7 increases the risk of autoimmune reactions in some patients. HLA-DR4 is the most frequently associated with autoimmune pancreatitis [22, 23].

HLA-DR is the only class II HLA reported to be up-regulated in CF patients with nasal polyps and associated with CF-related diseases such as coeliac disease [24-26]. Moreover, the HLA-DR4 and DR7 alleles were significantly higher in CF patients in Europe [27]. In the current study we hypothesized that HLA class II alleles will be associated with susceptibility to CF, or CF infections, in Iranian CF patients. We aimed, therefore, to examine the association of HLA-DR alleles with infectious agents such as *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Candida albicans* in correlation with serum levels of total IgE.

Materials And Methods

Patient's assembly

Our study was conducted on 50 CF patients (27 male, 23 female, 15.5 ± 6.5 years) who were referred to the Masih Daneshvari Hospital in Tehran-Iran from March 2017 to April 2018. The diagnosis of CF was confirmed using a combination of physical examination, clinical history (based on the ERS guidelines 2017) and lab tests as described previously [28]. Patients with diagnostic criteria other than CF were excluded from this study. 50 age- (9.96 ± 7.19) and gender-matched healthy individuals were also examined as a control group. Healthy individuals with a family background of CF were excluded. The study was approved by Ethical committee of Masih Daneshvari Hospital IR.SBMU.NRITLD.1395.234 and was in compliance with the national legislation and Declaration of Helsinki guidelines. Written informed consent was obtained from study participants and all necessary patient/participant consent and the appropriate institutional forms have been archived

Demographic data including age, gender, age at diagnosis, diabetes, gallstones, lung function tests (FVC and FEV1 obtained within the previous 6 months) and PaCO₂ and PaO₂ for these patients are given in **Table 1**.

DNA Extraction

Peripheral whole blood (5ml) was collected in an EDTA tube. DNA extraction was performed using a salting out method and the extracted samples were diluted with Tris 1M and H₂O. The DNA concentration was determined using a Nanodrop 2000 (Thermo Fisher, USA) and the samples stored at -70°C until analysis.

Microbiological studies

Sputum samples were analyzed for *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Candida Albicans* colonization by culture on Mannitol Salt Agar (*S. aureus*), on Muller-Hinton Agar (*P. aeruginosa*) or in SC medium (*C. Albicans*) in the Hospital microbiology center.

Serum IgE levels

Serum IgE levels was measured by ELISA (Pishtaz Teb Zaman, Tehran, Iran).

HLA typing

HLA-DR B1 subtypes whose gene products are recognized by DR4 were determined by Single Specific Primer Polymerase Chain Reaction (SSP-PCR methods) (Texas BioGene, USA) as described previously [29]. The PCR product was loaded onto a 1% agarose gel and the expression of the various alleles was visualized by Gel DOC (Bio-RAD, USA) according to the manufacturer's instructions. Identification of each individual alleles from the electrophoretic bands was performed by Morgan's SSPal HLA typing analysis software Ver2.5. In SSP-PCR, only primers that are fully complementary to the target sequence are amplified, and the presence of an amplified DNA fragment represents the presence of the specific allele in the genomic DNA.

Statistical analysis

Statistical analyses for frequencies of each allele were performed using the chi-square test and the confidence interval of the relative risk was done using the Koopman asymptotic score Method in GraphPad Prism (version 8.02) for HLA-DRB1 typing. Results were considered significant when $p \leq 0.05$.

Results

Analysis of the HLADR *B1-16 alleles

The presence of all HLA-DRB1-16 alleles was analyzed and representative results are shown (**Fig. 1**).

HLA-DRB1 allele frequency

The distribution of all alleles in CF patients and healthy controls are shown in **Table 2**. HLA-DRB1*10 and possibly HLA-DRB1*01, HLA-DRB1*09 and HLA-DRB1*12 are less frequent and HLA-DRB1*11, HLA-

DRB1*04 and HLA-DRB1*13 potentially more frequent in CF patients compared with healthy subjects. However, none of these differences reached statistical significance ($P \geq 0.05$).

Furthermore, non-significant effect of gender or age on HLA distribution was seen.

HLA-DRB1 and the level of total IgE

16 individuals had high serum levels of IgE (430.25 ± 219.7 IU/ml) and these subjects most commonly expressed the HLA-DRB1*04 allele (**Table 3**). Three CF patients had ABPA, of which two were DR4+, however, the small number of patients did not allow for further analysis.

Correlation of HLA-DRB1 frequency with *P. aeruginosa* and *C. Albicans* colonization

27/50 CF patients were colonized with *P. aeruginosa* within the lung and the HLA-DRB1*04 allele was the most frequent allele present in these subjects (**Table 3**). In contrast, 31/50 CF patients were colonized by *Candida albicans* with the most frequently associated allele being HLA-DRB1*11 (**Table 3**).

Correlations of HLA-DRB1 frequency with *C. Albicans* with level of total IgE and *P. Aeruginosa* with level of total IgE

14/50 patients had high levels of serum IgE and were colonized by *C. Albicans*. The HLA-DRB1*04 and HLA-DRB1*11 alleles were the most frequently found in these patients (**Table 3**). In contrast, the HLA-DRB1*04 allele was the most frequent allele present in the 10 *P. Aeruginosa* positive CF patients with high serum levels of total IgE (**Table 3**). The frequency of HLA-DRB1, other microbial colonizations and serum levels of IgE among CF patients are shown in **Table 3**.

Discussion

We report no significant enrichment of allele frequency in Iranian children with CF although there was a trend towards the HLA-DR11 and HLA-DR4 alleles being more common. In contrast, infection with *Pseudomonas* or *Candida* was more closely associated with HLA-DR4 and HLA-DR11 alleles respectively particularly in subjects with high serum IgE levels. CF children with high levels of serum CRP expressed lower levels of HLA-DR4 and HLA-DQ.

Although early studies indicated an association between HLA-DR4 and CF [27], our current data that shown there were no significant differences in the distribution of the alleles in 50 Iranian CF patients compared with the control group is in line with other, more recent, studies where no association between HLA class 1 and 2 with CF have been observed [6, 30-36]. Future studies should examine whether there is any link to disease severity.

Our results show a higher frequency of HLA-DR4 in patients with *Pseudomonas aeruginosa* colonization. *Pseudomonas* is the most important factor in causing infection in CF patients [37] and this may directly reflect CFTR dysfunction within the membrane decreasing the expression of defense proteins and

enhancing susceptibility to this infection [38]. Previous studies indicate that HLA-DR7 is the most frequent allele in patients with CF colonized with pseudomonas [27] suggesting that the resistance and susceptibility to *P. aeruginosa* could be attributed to the HLA class 2 loci in CF patients. The mechanism(s) by which reduced expression of HLA-DR and HLA-DQ in CF patients [1] provides suitable conditions for *P. aeruginosa* colonization is uncertain.

The HLA-DRB1*04 allele was more abundant in the 16 CF patients that expressed high levels of serum IgE. These data are in contrast to the greater prevalence of DR7 as the most frequent allele in a French population of CF patients with high levels of IgE [27]. In our patients, the DR4 allele was observed to a greater extent among patients with both high IgE levels and *P. aeruginosa* colonization.

ABPA is often observed in patients with asthma and CF due to the colonization of *aspergillus fumigatus* in the lower respiratory system [39]. The pathogenesis of ABPA includes reduced mucociliary clearance, impairment of fungicidal proteins, attenuated levels of complement in the respiratory tract and suppression of phagocytosis [40]. In our study only 3 patients out of the 12 colonized with *aspergillus* had ABPA. Although HLA-typing among these patients showed that 2 out of 3 patients had an HLA-DRB1*04 allele the numbers are too small to draw valid conclusions. However, previous studies have suggested that a high frequency of DR2 and DR5 is related to the development of ABPA [41]. Moreover, 84% of patients with ABPA-CF have HLA-DRB1*15:01, DRB1*11:04, DRB1*11:01, DRB1*07:01 and DRB1*04 alleles in comparison with CF and asthma [42]. In contrast, HLA-DQB1*02:01 was found as an ABPA-resistant allele [42].

Certain alleles of class II HLA may affect T helper cell (Th1, Th2) responses to *Aspergillus fumigatus*. The Th1 response and the subsequent production of antibodies may have a protective effect against *aspergillus* and activating a Th2 response leads to the release of cytokines and immunoglobulins which cause allergic inflammation [42-44]. Indeed, the T-cell response to *Aspergillus* allergens causes a Th2 response with the secretion of IL-4, IL-5 and IL-13 cytokines for IgE production [41]. Increased IL-5 release can eventually lead to reduced production of interferon (IFN)- γ [41-43] and so antigen-presentation by HLA-DRB1*04 may skew the immune response towards a Th2 response with an associated increase in total IgE levels [45].

In conclusion, we found no significant association between DR4 and DR11 and CF although there is an association with disease phenotypes including species of colonization and IgE levels. Further, large studies are required to understand the different aspects of CF clinical manifestations and these are impacted by specific HLA class 2 alleles.

Abbreviations

CF: Cystic fibrosis

CFTR: Cystic fibrosis transmembrane conductance regulator

HLA: Human Leukocyte Antigen

ABPA: Allergic bronchopulmonary aspergillosis

INF: Interferon

Declarations

Ethics approval and consent to participate

The study was approved by Ethical committee of Masih Daneshvari Hospital IR.SBMU.NRITLD.1395.234 and that written informed consent was obtained from study participants. All necessary patient/participant consent and the appropriate institutional forms have been archived and the principles of Helsinki's declaration were adhered to throughout the survey.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The author indicates has not any competing interest.

Authors' contributions

AA, EM and IMA designed the study and wrote the manuscript. AA performed the lab work. HAG made the clinical diagnosis of CF patients and provided the samples. IMA, edited the work and provided expert comments. AA, EM, HAG, HJ and MV contributed to the sample collection, data analysis and interpretation. All authors have read and approved the final manuscript.

Acknowledgements

IMA is supported by the Wellcome Trust (093080/Z/10/Z).

Funding:

No funding to declare.

Conflict of interest statement: The authors have no conflicts of interest.

References

1. Hofer TP, Frankenberger M, Heimbeck I, Burggraf D, Wjst M, Wright AK, Kerscher M, Nahrig S, Huber RM, Fischer R *et al*: **Decreased expression of HLA-DQ and HLA-DR on cells of the monocytic lineage**

- in cystic fibrosis.** *Journal of molecular medicine (Berlin, Germany)* 2014, **92**(12):1293-1304.
2. Nagano Y, Millar BC, Johnson E, Goldsmith CE, Elborn JS, Rendall J, Moore JE: **Fungal infections in patients with cystic fibrosis.** *Reviews in Medical Microbiology* 2007, **18**(1):11-16.
 3. Gallati S: **Disease-modifying genes and monogenic disorders: experience in cystic fibrosis.** *The Application of Clinical Genetics* 2014, **7**:133-146.
 4. Stern RC: **The diagnosis of cystic fibrosis.** *The New England journal of medicine* 1997, **336**(7):487-491.
 5. Kerem B, Rommens J, Buchanan J, Markiewicz D, Cox T, Chakravarti A, Buchwald M, Tsui L: **Identification of the cystic fibrosis gene: genetic analysis.** *Science* 1989, **245**(4922):1073-1080.
 6. Tobin MJ, Maguire O, Reen D, Tempany E, Fitzgerald MX: **Atopy and bronchial reactivity in older patients with cystic fibrosis.** *Thorax* 1980, **35**(11):807-813.
 7. Warner JO, Taylor BW, Norman AP, Soothill JF: **Association of cystic fibrosis with allergy.** *Archives of Disease in Childhood* 1976, **51**(7):507-511.
 8. Stenbit A, Flume PA: **Pulmonary Complications in Adult Patients With Cystic Fibrosis.** *The American Journal of the Medical Sciences* 2008, **335**(1):55-59.
 9. Coutinho HDM, Falcão-Silva VS, Gonçalves GF: **Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers.** *International Archives of Medicine* 2008, **1**:24.
 10. Sabino R, Carolino E, Moss RB, Banaei N, Verissimo C, Stevens DA: **Susceptibility of Candida albicans from Cystic Fibrosis Patients.** *Mycopathologia* 2017.
 11. Maiz L, Cuevas M, Quirce S, Canon JF, Pacheco A, Sousa A, Escobar H: **Serologic IgE immune responses against Aspergillus fumigatus and Candida albicans in patients with cystic fibrosis.** *Chest* 2002, **121**(3):782-788.
 12. Shiina T, Hosomichi K, Inoko H, Kulski JK: **The HLA genomic loci map: expression, interaction, diversity and disease.** *Journal of human genetics* 2009, **54**(1):15-39.
 13. Mack DG, Johnson JJ, Roberts F, Roberts CW, Estes RG, David C, Grumet FC, McLeod R: **HLA-class II genes modify outcome of Toxoplasma gondii infection.** *International journal for parasitology* 1999, **29**(9):1351-1358.
 14. Petzl-Erler ML, Belich MP, Queiroz-Telles F: **Association of mucosal leishmaniasis with HLA.** *Human immunology* 1991, **32**(4):254-260.
 15. Hill AV, Elvin J, Willis AC, Aidoo M, Allsopp CE, Gotch FM, Gao XM, Takiguchi M, Greenwood BM, Townsend AR *et al*: **Molecular analysis of the association of HLA-B53 and resistance to severe malaria.** *Nature* 1992, **360**(6403):434-439.
 16. Zhang Y, Peng Y, Yan H, Xu K, Saito M, Wu H, Chen X, Ranasinghe S, Kuse N, Powell T *et al*: **Multilayered defense in HLA-B51-associated HIV viral control.** *Journal of immunology (Baltimore, Md : 1950)* 2011, **187**(2):684-691.

17. Lincoln MR, Montpetit A, Cader MZ, Saarela J, Dymment DA, Tiislar M, Ferretti V, Tienari PJ, Sadovnick AD, Peltonen L *et al*: **A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis.** *Nature genetics* 2005, **37**(10):1108-1112.
18. Gul A, Ohno S: **HLA-B*51 and Behcet Disease.** *Ocular immunology and inflammation* 2012, **20**(1):37-43.
19. Bell J, Rassenti L, Smoot S, Smith K, Newby C, Hohlfeld R, Toyka K, McDevitt H, Steinman L: **HLA-DQ beta-chain polymorphism linked to myasthenia gravis.** *Lancet (London, England)* 1986, **1**(8489):1058-1060.
20. Aron Y, Swierczewski E, Lockhart A: **A simple and rapid micromethod for genomic DNA extraction from jugal epithelial cells.** *Allergy* 1994, **49**(9):788-790.
21. Aron Y, Swierczewski E, Lockhart A: **HLA class II haplotype in atopic asthmatic and non-atopic control subjects.** *Clinical & Experimental Allergy* 1995, **25**:65-67.
22. Petri M: **CHAPTER 27 - Systemic Lupus Erythematosus and Related Diseases: Clinical Features.** In: *The Autoimmune Diseases (Fourth Edition)*. edn. Edited by Rose NR, Mackay IR. St. Louis: Academic Press; 2006: 351-356.
23. Al-Shura AN: **Chapter 14 - Rheumatic Heart Disease.** In: *Integrative Cardiovascular Chinese Medicine*. edn. Edited by Al-Shura AN. Boston: Academic Press; 2014: 217-225.
24. Wang D, Levasseur-Acker GM, Jankowski R, Kanny G, Moneret-Vautrin DA, Charron D, Lockhart A, Swierczewski E: **HLA class II antigens and T lymphocytes in human nasal epithelial cells. Modulation of the HLA class II gene transcripts by gamma interferon.** *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 1997, **27**(3):306-314.
25. Fluge G, Olesen HV, Gilljam M, Meyer P, Pressler T, Storrosten OT, Karpati F, Hjelte L: **Co-morbidity of cystic fibrosis and celiac disease in Scandinavian cystic fibrosis patients.** *Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society* 2009, **8**(3):198-202.
26. Walkowiak J, Blask-Osipa A, Lisowska A, Oralewska B, Pogorzelski A, Cichy W, Sapiejka E, Kowalska M, Korzon M, Szaflarska-Poplawska A: **Cystic fibrosis is a risk factor for celiac disease.** *Acta biochimica Polonica* 2010, **57**(1):115-118.
27. Aron Y, Polla BS, Bienvenu T, Dall'ava J, Dusser D, Hubert D: **HLA class II polymorphism in cystic fibrosis. A possible modifier of pulmonary phenotype.** *American journal of respiratory and critical care medicine* 1999, **159**(5 Pt 1):1464-1468.
28. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K *et al*: **European Respiratory Society guidelines for the management of adult bronchiectasis.** *European Respiratory Journal* 2017, **50**(3):1700629.
29. Mortaz E, Sereshki HA, Abedini A, Kiani A, Mirsaeidi M, Soroush D, Garssen J, Velayati A, Redegeld FA, Adcock IM: **Association of serum TNF-alpha, IL-8 and free light chain with HLA-DR B alleles expression in pulmonary and extra-pulmonary sarcoidosis.** *Journal of inflammation (London, England)* 2015, **12**:21.

30. Adriaanse MP, Vreugdenhil AC, Groeneweg M, Bruggenwirth HT, Castelijns SJ, van der Ent CK, Voorter CE, Tilanus MG: **HLA frequencies and associations in cystic fibrosis.** *Tissue antigens* 2014, **83**(1):27-31.
31. Säfwenbergs J, Kollberg H, Lindblom JB: **HLA Frequencies in Patients with Cystic Fibrosis.** *Tissue antigens* 1977, **10**(4):287-290.
32. Hennequet A, Jehanne M, Betuel H, Gilly R, Schmid M, Hors J: **Cystic fibrosis and HLA.** *Tissue antigens* 1978, **12**(3):159-162.
33. Turner MW, Warner JO, Stokes CR, Norman AP: **Immunological studies in cystic fibrosis.** *Archives of Disease in Childhood* 1978, **53**(8):631-638.
34. Stutchfield PR, O'Halloran SM, Smith CS, Woodrow JC, Bottazzo GF, Heaf D: **HLA type, islet cell antibodies, and glucose intolerance in cystic fibrosis.** *Archives of Disease in Childhood* 1988, **63**(10):1234-1239.
35. Jones MM, Seilheimer DK, Pollack MS, Curry M, Crane MM, Rossen RD: **Relationship of hypergammaglobulinemia, circulating immune complexes, and histocompatibility antigen profiles in patients with cystic fibrosis.** *The American review of respiratory disease* 1989, **140**(6):1636-1639.
36. Witt M, Erickson RP, Ober C, Howatt WF, Farber R: **Correlation of phenotypic and genetic heterogeneity in cystic fibrosis: variability in sweat electrolyte levels contributes to heterogeneity and is increased with the XV-2c/KM19 B haplotype.** *American journal of medical genetics* 1991, **39**(2):137-143.
37. Davies JC: **Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence.** *Paediatric respiratory reviews* 2002, **3**(2):128-134.
38. Pier GB: **Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections.** *Proceedings of the National Academy of Sciences of the United States of America* 2000, **97**(16):8822-8828.
39. Janahi IA, Rehman A, Al-Naimi AR: **Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.** *Annals of thoracic medicine* 2017, **12**(2):74-82.
40. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ: **Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon.** *Infection and Immunity* 1993, **61**(11):4870-4877.
41. Knutsen AP, Bellone C, Kauffman H: **Immunopathogenesis of allergic bronchopulmonary aspergillosis in cystic fibrosis.** *Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society* 2002, **1**(2):76-89.
42. Muro M, Mondejar-Lopez P, Moya-Quiles MR, Salgado G, Pastor-Vivero MD, Lopez-Hernandez R, Boix F, Campillo JA, Minguella A, Garcia-Alonso A *et al*: **HLA-DRB1 and HLA-DQB1 genes on susceptibility to and protection from allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.** *Microbiology and immunology* 2013, **57**(3):193-197.
43. Patterson K, Strek ME: **Allergic bronchopulmonary aspergillosis.** *Proceedings of the American Thoracic Society* 2010, **7**(3):237-244.

44. Knutsen AP, Chauhan B, Slavin RG: **Cell-mediated immunity in bronchopulmonary aspergillosis.** *Immunology and Allergy Clinics of North America* 1998, **18**(3):575-599.
45. Cardaba B, De Pablo R, Vilches C, Martin E, Geller-Bernstein C, De Andres B, Zaharan Y, Del Pozo V, Gallardo S, De Arruda Chaves E *et al*: **Allergy to olive pollen: T-cell response from olive allergic patients is restricted by DR7-DQ2 antigens.** *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 1996, **26**(3):316-322.

Tables

Table 1: Demographic data of CF patients

<i>Healthy control subjects</i>	<i>Cystic fibrosis patient</i>	
Demographic data		
50	50	<i>Number of subjects</i>
9.96 ± 7.19	15.5 ± 6.5	<i>Age (mean ± SD) years</i>
—	8 ± 7.3	<i>Age at diagnosis, yr</i>
		<i>Sex</i>
27	27	<i>male</i>
23	23	<i>female</i>
Respiratory data		
—	49.3 ± 22.5	<i>FVC, % pred</i>
—	47.2 ± 24.9	<i>FEV1, % pred</i>
—	47.1 ± 23.8	<i>PaO₂, mm Hg</i>
—	43.6 ± 14.2	<i>PaCO₂, mm Hg</i>
Comorbidities		
—	210.59 ± 246	<i>IgE, IU/ml</i>
—	2	<i>Diabetes, n</i>
—	2	<i>Gallstone, n</i>
Microbiological data		
—	27	<i>P. aeruginosa colonization, n</i>
—	12	<i>Staphylococcus aureus</i>
—	31	<i>Candida colonization, n</i>

FEV1: forced expiratory volume in 1 second

FVC: Forced vital capacity

Normal serum levels of IgE for adults are < 150 UI/ml.

Table 2: Frequency of HLA-DRB1 in control and CF patients

		<i>Healthy controls</i>		<i>CF patients</i>		HLADRB1
<i>RR</i>	<i>P value</i>	<i>%</i>	<i>n</i>	<i>%</i>	<i>n</i>	
0.55	0.23	10	5	4	2	<i>DRB1*01</i>
1.15	0.58	14	7	18	9	<i>DRB1*03</i>
1.35	0.16	18	9	30	15	<i>DRB1*04</i>
0.93	0.79	18	9	16	8	<i>DRB1*07</i>
0.46	0.46	6	3	10	5	<i>DRB1*08</i>
2.04	0.15	0	0	4	2	<i>DRB1*09</i>
0.48	0.30	6	3	2	1	<i>DRB1*10</i>
1.17	0.41	36	18	44	22	<i>DRB1*11</i>
0.42	0.15	0	0	4	2	<i>DRB1*12</i>
1	0.99	22	11	22	11	<i>DRB1*13</i>
1.17	0.56	12	6	16	8	<i>DRB1*14</i>
1.12	0.61	18	9	22	11	<i>DRB1*15</i>
0.70	0.33	14	7	8	4	<i>DRB1*16</i>

Table 3: Various microbial colonization and level of IgE among CF patients

High total IgE & P. Aeruginosa	High total IgE & C. Albicans	S. aureus	Total IgE	C. Albicans	P. Aeruginosa	
(n)	(n)	(n)	(n)	(n)	(n)	HLADRB1
0	0	1	1	0	0	<i>DRB1*01</i>
2	3	1	3	7	4	<i>DRB1*03</i>
5	5	5	9	9	11	<i>DRB1*04</i>
0	2	3	2	5	3	<i>DRB1*07</i>
0	0	0	0	3	2	<i>DRB1*08</i>
0	0	0	0	1	0	<i>DRB1*09</i>
0	0	0	0	0	0	<i>DRB1*10</i>
1	5	9	6	11	8	<i>DRB1*11</i>
1	1	0	1	1	0	<i>DRB1*12</i>
4	4	1	4	8	7	<i>DRB1*13</i>
3	3	1	3	7	5	<i>DRB1*14</i>
1	2	5	2	9	8	<i>DRB1*15</i>
1	1	0	1	3	3	<i>DRB1*16</i>

Figures

Figure 1

Representative gel electrophoresis of PCR products. Gel electrophoresis showing amplification profile of DNA samples of CF patients. The product size in bp refers to the amplification of a selective allele. The presence of different Positive amplification in each sample indicates a specific allele. In this figure amplification in wells number 9, 10, 22 shows DRB1*11:01, DRB1*11:05 allele. Detection of allele-specific amplified bands in 1% agarose gel by single specific primer-polymerase chain reaction (SSP-PCR). The internal control represents a conserved region of the house keeping gene (provided in kit) and serves as an indication.